Clinical trials: Acute Primary Angle-closure Glaucoma
Glaucoma, Angle-closure, Primary, Acute
Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)
This study will assess any side effects that may occur when QPI-1007 is injected into the eye in subjects with acute primary angle-closure glaucoma, as well as how long it takes for the body to clear the drug.
- Trial name
- NCT01965106
- Testing
- QPI-1007 Injection
- Where
- 8 sites in United States, Singapore and 1 more
- Volunteers
- 46 people
- Sponsor
- Quark Pharmaceuticals